76 related articles for article (PubMed ID: 20393402)
21. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients.
Marcén R; Caballero C; Uriol O; Fernández A; Villafruela JJ; Pascual J; Martins J; Rodriguez N; Burgos FJ; Ortuño J
Transplant Proc; 2007 Sep; 39(7):2256-8. PubMed ID: 17889156
[TBL] [Abstract][Full Text] [Related]
23. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
[TBL] [Abstract][Full Text] [Related]
24. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Neurology; 2005 Mar; 64(5):811-6. PubMed ID: 15753414
[TBL] [Abstract][Full Text] [Related]
25. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
26. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
27. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
28. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
30. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation.
Grotz WH; Mundinger FA; Gugel B; Exner VM; Kirste G; Schollmeyer PJ
Transplantation; 1995 Apr; 59(7):982-6. PubMed ID: 7709459
[TBL] [Abstract][Full Text] [Related]
31. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
Izumi K; Mizokami A; Sugimoto K; Narimoto K; Miwa S; Maeda Y; Kadono Y; Takashima M; Koh E; Namiki M
Urology; 2009 Jun; 73(6):1342-6. PubMed ID: 19371939
[TBL] [Abstract][Full Text] [Related]
32. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
[TBL] [Abstract][Full Text] [Related]
33. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.
Tauchmanovà L; Selleri C; Esposito M; Di Somma C; Orio F; Bifulco G; Palomba S; Lombardi G; Rotoli B; Colao A
Osteoporos Int; 2003 Dec; 14(12):1013-9. PubMed ID: 14517597
[TBL] [Abstract][Full Text] [Related]
34. Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients.
Sánchez-Escuredo A; Fuster D; Rubello D; Muxí A; Ramos A; Campos F; Marzola MC; Cook GJ; Tapias A; Torregrosa JV
Nucl Med Commun; 2015 Aug; 36(8):815-8. PubMed ID: 25856225
[TBL] [Abstract][Full Text] [Related]
35. Response of bone mineral density to once-weekly administration of risedronate.
Gordon MS; Gordon MB
Endocr Pract; 2002; 8(3):202-7. PubMed ID: 12113633
[TBL] [Abstract][Full Text] [Related]
36. Effect of risedronate on bone in renal transplant recipients.
Coco M; Pullman J; Cohen HW; Lee S; Shapiro C; Solorzano C; Greenstein S; Glicklich D
J Am Soc Nephrol; 2012 Aug; 23(8):1426-37. PubMed ID: 22797188
[TBL] [Abstract][Full Text] [Related]
37. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study.
De Sévaux RG; Hoitsma AJ; Corstens FH; Wetzels JF
J Am Soc Nephrol; 2002 Jun; 13(6):1608-14. PubMed ID: 12039990
[TBL] [Abstract][Full Text] [Related]
38. Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D.
Van Cleemput J; Daenen W; Geusens P; Dequeker P; Van De Werf F; VanHaecke J
Transplantation; 1996 May; 61(10):1495-9. PubMed ID: 8633378
[TBL] [Abstract][Full Text] [Related]
39. The role of risedronate in osteopenia in Crohn's disease.
Buchan A; Manuel A
Gut; 2015 Jan; 64(1):185. PubMed ID: 24304669
[No Abstract] [Full Text] [Related]
40. Authors' response: The role of risedronate in osteopenia in Crohn's disease.
van Bodegraven AA; Witte BI; Lips P;
Gut; 2015 Jan; 64(1):185-6. PubMed ID: 24569060
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
